about
Medication adherence in gout: a systematic reviewA review of uric acid, crystal deposition disease, and gout.What Outcomes are Important for Gout Patients? In-Depth Qualitative Research into the Gout Patient Experience to Determine Optimal Endpoints for Evaluating Therapeutic Interventions.Treatment approaches and adherence to urate-lowering therapy for patients with gout.Decrystallization of Crystals Using Gold "Nano-Bullets" and the Metal-Assisted and Microwave-Accelerated Decrystallization TechniqueUric acid and evolution.Urate lowering therapy with febuxostat in daily practice-a multicentre, open-label, prospective observational study.2011 recommendations for the diagnosis and management of gout and hyperuricemia.Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout.Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?Role of the NLRP3 inflammasome in the transient release of IL-1β induced by monosodium urate crystals in human fibroblast-like synoviocytes.Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional surveyAn Independent Risk of Gout on the Development of Deep Vein Thrombosis and Pulmonary Embolism: A Nationwide, Population-Based Cohort Study."You want to get on with the rest of your life": a qualitative study of health-related quality of life in gout.Validation of claims-based algorithms for gout flares.Development and First Validation of a Disease Activity Score for Gout.Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR).Difficult-to-treat gouty arthritis: a disease warranting better management.Recent advances in management of gout.Canakinumab in gout.Evaluation and treatment of gout as a chronic disease.Optimizing current treatment of gout.Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters.Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study.Management of gout in the real world: current practice versus guideline recommendations.A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift.Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat.Cost-effectiveness of febuxostat in chronic gout.Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.The Duality of Economic Issues With Medication Non-adherence in Patients With Inflammatory Arthritis.Gouty arthritis: decision-making following dual-energy CT scan in clinical practice, a retrospective analysis.Pilot study of a multidisciplinary gout patient education and monitoring program.Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.Temporal evolution of urate crystal deposition over articular cartilage after successful urate-lowering therapy in patients with gout: An ultrasonographic perspective.Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.Pharmacists' assessment and management of acute and chronic gout.
P2860
Q27694691-7C3C4183-B137-46AC-8BC2-86579FF94998Q30619265-2EE2C0DC-CED4-4FEA-AA57-5F9B2105F940Q30835709-C283C775-60F1-42B6-ACD7-8AA94EDBCCB4Q33597442-E0FA55A8-A88D-4820-BFB8-6270B52179AFQ33615722-60D33ABC-24BF-44A9-8AB6-936E10CFD97CQ34125842-9B03CB01-6404-4F2D-AAD8-12E35EBADDA7Q34207190-C89A2B92-2CBF-470A-BF50-505CF65046FDQ34250995-89E419B2-985D-4348-9B57-34AE200AA5DAQ34415029-484DA0D5-1BC8-4B22-A30B-8AEFED1AE39DQ34538414-894A8EC0-FE3F-49A8-9B44-B87166A8ECFDQ35495434-9168D45E-2D8B-4B30-9E14-C000026292B7Q36402266-E6076D5A-4E53-4AAA-AFF6-C9F54B359700Q36420970-E19A733A-3CF3-4AB6-A878-D84225C8960BQ36834494-163A264B-430C-48DB-A6DF-91B784557ABAQ37059151-645B0937-9FFD-49EA-81BD-991E58D15599Q37456293-BD3BCBD5-A5A3-4DE4-93E1-DA6BC4900175Q37553140-D96D4A8E-C845-4FC4-ACB5-AD7188234803Q37691084-10125A18-78FA-4536-A8AB-22EC76BAD4E5Q37910901-9F0CFBB7-F230-43BA-A3E7-3DAD7EB6EC02Q37971360-823F9684-0120-4BC3-A1C7-65FC5F6BE479Q38025456-B71E0E1B-CF5E-48E7-A4EE-678DF37E8B34Q38056075-8116E51C-D375-450B-BA56-46B319952D2EQ38194896-55C24582-C87C-4D72-8350-9ACBC617D29FQ38658478-0ABA7281-8C11-40DB-B1B8-A3A118536BDBQ38759840-C802ABA6-98F5-4F1A-B84B-E32605572867Q38788228-5D0845B4-BF6C-4954-93F9-760E1819DA9AQ39805127-6129BA6E-0D29-4297-AC21-01D5208AD1ACQ40291328-C8B2D5C0-0237-44F2-8F74-50C924772E85Q40311349-3017B2E3-B342-45EE-B9B0-0ED07F912D72Q41174839-AA77272E-CDF4-426B-8F65-E95D79687E5CQ42688139-15A5D334-4632-4405-84A5-07B88C3F1DF8Q46847933-EBFA8707-8756-49BC-AE62-6AE37B2A70FCQ47658083-1C5958A8-51D1-4AE8-9D6E-A01929010F7CQ47943997-AE8AF514-2B89-4B8D-936A-9A6AC155285AQ48043574-F0EC7AE6-24D1-40CC-A445-AA4F7468DEF3Q50111167-6000190C-F90F-4FE1-A866-30B92ACB0A8DQ53583024-1C56CD91-08D8-4B71-AAB1-50F5CA60C69EQ53754811-8EB59B56-A488-4FC9-B960-831135E0F460Q53837944-C5FEC928-9BFE-402C-8B02-857ECDD6F9E5Q54935963-AB955CB5-E9EB-44F5-9754-228BA8FA9C0A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treating to target: a strategy to cure gout.
@en
Treating to target: a strategy to cure gout.
@nl
type
label
Treating to target: a strategy to cure gout.
@en
Treating to target: a strategy to cure gout.
@nl
prefLabel
Treating to target: a strategy to cure gout.
@en
Treating to target: a strategy to cure gout.
@nl
P2860
P356
P1433
P1476
Treating to target: a strategy to cure gout.
@en
P2860
P304
P356
10.1093/RHEUMATOLOGY/KEP087
P478
48 Suppl 2
P577
2009-05-01T00:00:00Z